Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 7, 2009, Pages 3233-3237

  Memarzadeh, Farnaz ^a   Varma, Rohit ^a,b   Lin, Le Tien ^c   Parikh, Jignesh G ^a   Dustin, Laurie ^b   Alcaraz, Ana ^d   Eliott, Dean ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; SODIUM CHLORIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC ANTIMETABOLITE; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HISTOPATHOLOGY; NONHUMAN; OCULAR FIBROSIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; SCAR FORMATION; SURVIVAL TIME; THERAPY EFFECT; TRABECULOTOMY; ANIMAL; CONJUNCTIVA; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; FIBROBLAST; FIBROSIS; GLAUCOMA; INJECTION; INTRAOCULAR PRESSURE; PATHOLOGY; PROGNOSIS; RABBIT; SCLERA; TRABECULECTOMY; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; CONJUNCTIVA; DISEASE MODELS, ANIMAL; FIBROBLASTS; FIBROSIS; FLUOROURACIL; GLAUCOMA; INJECTIONS; INTRAOCULAR PRESSURE; POSTOPERATIVE CARE; PROGNOSIS; RABBITS; SCLERA; TRABECULECTOMY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 67649949015     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2441     Document Type: Article

References (24)

1. Skuta GL, Parrish RK. Wound healing in glaucoma filtering surgery. Surv Ophthalmol. 1987;32:149-170.
2. Hitchings RA, Grierson I. Clinicophathological correlation in eyes with failed fistulizing surgery. Trans Opthalmol Soc UK. 1983;103: 84-88.
3. Migdal C, Gregory W, Hitchings R. Long-term functional outcome after early surgery compared with laser and medicine in openangle glaucoma. Ophthalmology. 1994;101:1651-1656.
4. Crowston JG, Akbar AN, Constable PH, et al. Antimetabolite-induced apoptosis in Tenon's capsule fibroblasts. Invest Ophthalmol Vis Sci. 1998;39:449-454.
5. Yamamoto T, Varani J, Soong HK, Lichter PR. Effects of 5-FU and mitomycin C on cultured rabbit subconjunctival fibroblasts. Ophthalmology. 1990;97:1204-1210.
6. Seah SK, Prata JA Jr, Minckler DS, et al. Hypotony following trabeculectomy. J Glaucoma. 1995;4:73.
7. Parrish R, Minckler D. 'Late endophthalmitis': filtering surgery time bomb? Ophthalmology. 1996;103:1167-1168.
8. Li J, Zhang YP, Kirsner RS. Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix. Microsc Res Tech. 2003;60:107.
9. Asahara T, Bauters C, Zheng LP, et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circluation. 1995;92(suppl):II365-II371.
10. Wong J, Wang N, Miller JW, Schuman JS. Modulation of human fibroblast activity by selected angiogenesis inhibitors. Exp Eye Res. 1994;58:439-451.
11. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
12. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142:155-158.
13. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372.
14. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina. 2006;26:354-356.
15. Jonas JB, Spandau UH, Schlichtenbrede F. Intravitreal bevacizumab for filtering surgery. Ophthalmic Res. 2007;39:121-122.
16. Kahook MY, Schuman JS, Noecker RJ. Needle bleb revision of encapsulated filtering bleb with bevacizumab. Ophthalmic Surg Lasers Imaging. 2006;37:148-150.
17. Mead AL, Wong TTL, Cordeiro F, Anderson IK, Khaw PT. Evaluation of anti-TGF-β2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003;44:3394-3401.
18. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56:549-580.
19. Pollina EA, Legesse-Miller A, Haley EM, Goodpaster T, Randolph-Habecker J, Coller HA. Regulating the angiogenic balance in tissues. Cell Cycle. 2008;7:2056-2070.
20. Wilgus TA, Ferreira AM, Oberyszyn TM, Bergdall VK, Dipietro LA. Regulation of scar formation by vascular endothelial growth factor. Lab Invest. 2008;88:579-590.
21. Miller MH, Grierson I, Unger WI, Hitchings RA. Wound healing in an animal model of glaucoma fistulizing surgery in the rabbit. Ophthalmic Surg. 1989;20:350-357.
22. Gresses MG, Parrish RK II, Folber R. 5-Flurouracil and glaucoma filtering surgery: an animal model. Ophthalmology. 1984;91:378-383.
23. Doyle JW, Sherwood MB, Khaw PT, McGrory S, Fran Smith M. Intraoperative 5-fluorouracil for filtration surgery in the rabbit. Invest Ophthalmol Vis Sci. 1993;34:3313-3319.
24. The Flourouracil Filtering Surgery Study Group. Five-year follow-up of the Flourouracil Filtering Surgery Study. Am J Ophthalmol. 1996;121:349-366.